Risankizumab Tops Competitor for Clinical Remission in Moderate-to-Severe CD

MedPage Today) — SAN FRANCISCO — More adults with moderate-to-severe Crohn’s disease (CD) reached clinical remission after 6 months on risankizumab (Skyrizi) versus ustekinumab (Stelara), according to a head-to-head trial.
In the phase III…